Crossref
Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis
Journal of Clinical Lipidology · 2026-06 · 20 (6) · e105-e106
DOI: 10.1016/j.jacl.2026.05.161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026-06. Verfasst von Adam Nelson und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Nelson, A., Kastelein, J., Ditmarsch, M., Kling, D., Ortiz, N., Wicks, D., Hsieh, A., Davidson, M., & Nicholls, S. (2026). Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis. Journal of Clinical Lipidology, 20(6), e105-e106. https://doi.org/10.1016/j.jacl.2026.05.161
Vancouver
Nelson A, Kastelein J, Ditmarsch M, Kling D, Ortiz N, Wicks D, et al. Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis. Journal of Clinical Lipidology. 2026;20(6):e105-e106. doi:10.1016/j.jacl.2026.05.161
BibTeX
@article{Nelson2026,
author = {Nelson, Adam and Kastelein, John and Ditmarsch, Marc and Kling, Douglas and Ortiz, Nancy and Wicks, Douglas and Hsieh, Andrew and Davidson, Michael and Nicholls, Stephen},
title = {Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {6},
pages = {e105--e106},
doi = {10.1016/j.jacl.2026.05.161}
}
EUVIMED